NCT05078060 - Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2021/22 | Biotech Hunter

Enrollment

1,804

Participants

Timeline

Start Date

October 12, 2021

Primary Completion Date

December 2, 2021

Study Completion Date

December 2, 2021

Conditions

Influenza (Healthy Volunteers)

Interventions

BIOLOGICAL

Quadrivalent Influenza Vaccine

Intramuscular or subcutaneous administration

BIOLOGICAL

High-Dose Quadrivalent Influenza Vaccine

Intramuscular administration

Trial Locations (15)

20099

Investigational Site Number :2760006, Hamburg

20100

Investigational Site Number :2-2-011, Turku

33100

Investigational Site Number :2-2-003, Tampere

36037

Investigational Site Number :2760002, Fulda

40100

Investigational Site Number :2-2-005, Jyväskylä

40470

Investigational Site Number :2760011, Düsseldorf

44789

Investigational Site Number :2760008, Bochum

60329

Investigational Site Number :2760007, Frankfurt am Main

70100

Investigational Site Number :2-2-004, Kuopio

78166

Investigational Site Number :2760001, Donaueschingen

85540

Investigational Site Number :2760004, Haar

90530

Investigational Site Number :2760009, Wendelstein

97506

Investigational Site Number :2760003, Grafenrheinfeld

99444

Investigational Site Number :2760005, Blankenhain

00180

Investigational Site Number :2-2-002, Helsinki

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY